Can Fite Biopharma (CANF) Trading Down 5.5%

Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) dropped 5.5% on Thursday . The stock traded as low as $1.98 and last traded at $2.25. Approximately 509,296 shares were traded during trading, an increase of 44% from the average daily volume of 352,786 shares. The stock had previously closed at $2.38.

CANF has been the subject of several analyst reports. Maxim Group set a $7.00 target price on Can Fite Biopharma and gave the company a “buy” rating in a report on Monday, January 8th. HC Wainwright set a $6.00 price objective on shares of Can Fite Biopharma and gave the stock a “buy” rating in a research note on Tuesday, October 31st.

The firm has a market cap of $37.46, a P/E ratio of 6.24 and a beta of 1.79.

Can Fite Biopharma (NYSEAMERICAN:CANF) last announced its earnings results on Monday, November 27th. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.09. Can Fite Biopharma had a negative net margin of 2,453.03% and a negative return on equity of 57.94%.

COPYRIGHT VIOLATION NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.com-unik.info/2018/02/03/can-fite-biopharma-canf-trading-down-5-5.html.

About Can Fite Biopharma

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit